Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Cyclacel Pharmaceuticals, Inc. | cycc-20191231ex3227a96df.htm |
| EX-32.1 - EX-32.1 - Cyclacel Pharmaceuticals, Inc. | cycc-20191231ex32179f4fb.htm |
| EX-31.2 - EX-31.2 - Cyclacel Pharmaceuticals, Inc. | cycc-20191231ex312b15d62.htm |
| EX-31.1 - EX-31.1 - Cyclacel Pharmaceuticals, Inc. | cycc-20191231ex3113c71c2.htm |
| EX-4.7 - EX-4.7 - Cyclacel Pharmaceuticals, Inc. | cycc-20191231ex47c4a9d09.htm |
| 10-K - 10-K - Cyclacel Pharmaceuticals, Inc. | cycc-20191231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Nos. 333-226906, 333-219055,333-205153, 333-183483, and 333-143786) on Form S-8 and (Nos. 333-231923, 333-211046 and 333-187801) on Form S-3 of Cyclacel Pharmaceuticals, Inc. of our report dated March 5, 2020, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ RSM US LLP
New York, New York
March 5, 2020